Michael H Davidson Selected Research

fenofibric acid

6/2014	Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
11/2012	Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
4/2012	One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
9/2011	Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). [email protected].
1/2010	Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
5/2009	Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
4/2009	Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael H Davidson Research Topics

Disease

49	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2005
44	Dyslipidemias (Dyslipidemia) 10/2021 - 11/2002
36	Coronary Disease (Coronary Heart Disease) 09/2021 - 06/2002
28	Atherosclerosis 01/2018 - 07/2003
26	Hypertriglyceridemia 09/2021 - 01/2003
21	Hypercholesterolemia 09/2021 - 01/2002
17	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 11/2002
14	Type 2 Diabetes Mellitus (MODY) 05/2021 - 01/2006
11	Myocardial Infarction 09/2021 - 01/2005
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2012 - 06/2005
10	Diabetes Mellitus 10/2021 - 01/2006
10	Rhabdomyolysis 09/2016 - 09/2002
9	Muscular Diseases (Myopathy) 06/2014 - 09/2002
8	Stroke (Strokes) 09/2021 - 01/2005
7	Inflammation (Inflammations) 01/2022 - 12/2007
6	Hyperlipidemias (Hyperlipidemia) 08/2015 - 03/2003
5	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2018 - 12/2005
5	Hypertension (High Blood Pressure) 04/2013 - 01/2005
5	Vascular Diseases (Vascular Disease) 08/2011 - 07/2003
4	Myotoxicity 01/2006 - 09/2002
3	Acute Coronary Syndrome 01/2021 - 01/2005
3	Ischemic Stroke 12/2016 - 12/2007
3	Myalgia 08/2014 - 01/2005
3	Heart Diseases (Heart Disease) 04/2013 - 03/2002
3	Obesity 10/2011 - 12/2002
3	Insulin Resistance 11/2010 - 01/2006
2	Rupture 01/2022 - 06/2008
2	Genetic Risk Score 01/2020 - 10/2018
2	Chronic Renal Insufficiency 01/2019 - 05/2009
2	Pancreatitis 03/2018 - 03/2008
2	Unstable Angina 12/2016 - 12/2007
2	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 06/2015 - 03/2015
2	Body Weight (Weight, Body) 12/2014 - 12/2002
2	Heart Failure 05/2014 - 12/2011
2	Inborn Genetic Diseases (Disease, Hereditary) 12/2013 - 04/2013
2	Hyperglycemia 09/2013 - 01/2009
2	Weight Loss (Weight Reduction) 04/2013 - 12/2002
2	Thrombosis (Thrombus) 08/2012 - 12/2007

Drug/Important Bio-Agent (IBA)

56	LipidsIBA 09/2021 - 01/2003
56	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 09/2002
36	oxidized low density lipoproteinIBA 09/2021 - 11/2003
32	HDL CholesterolIBA 12/2020 - 01/2003
31	LDL CholesterolIBA 01/2018 - 03/2003
30	Triglycerides (Triacylglycerol)IBA 09/2021 - 12/2002
28	CholesterolIBA 09/2016 - 03/2002
22	Lipoproteins (Lipoprotein)IBA 09/2021 - 08/2004
20	Simvastatin (Zocor)FDA LinkGeneric 09/2016 - 12/2002
15	Ezetimibe (Zetia)FDA Link 01/2019 - 12/2002
15	Rosuvastatin Calcium (Crestor)FDA Link 11/2012 - 03/2003
14	Atorvastatin (Lipitor)FDA Link 06/2014 - 03/2003
13	LDL Lipoproteins (beta Lipoproteins)IBA 11/2016 - 03/2003
11	Pharmaceutical PreparationsIBA 01/2022 - 03/2002
11	Niacin (Nicotinic Acid)FDA LinkGeneric 09/2013 - 03/2003
10	Biomarkers (Surrogate Marker)IBA 10/2018 - 04/2008
10	ApolipoproteinsIBA 01/2018 - 03/2003
10	Fibric Acids (Fibrates)IBA 06/2014 - 03/2003
9	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2021 - 08/2006
9	Fenofibrate (CiL)FDA LinkGeneric 06/2014 - 06/2003
8	Fatty Acids (Saturated Fatty Acids)IBA 05/2021 - 12/2002
8	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 09/2015 - 04/2008
8	HDL LipoproteinsIBA 09/2011 - 03/2003
7	fenofibric acid FDA Link 06/2014 - 04/2009
6	Carboxylic AcidsIBA 12/2020 - 09/2014
6	Coenzyme A (CoA)IBA 01/2009 - 01/2003
5	Adenosine Triphosphate (ATP)IBA 09/2013 - 03/2002
5	EstersIBA 09/2013 - 07/2007
4	lipoprotein cholesterolIBA 11/2019 - 10/2009
4	Eicosapentaenoic AcidIBA 12/2016 - 12/2011
4	Apolipoprotein A-I (Apolipoprotein A1)IBA 02/2015 - 03/2003
4	Apolipoproteins B (ApoB)IBA 12/2014 - 03/2003
4	Bile Acids and Salts (Bile Acids)IBA 01/2014 - 04/2008
4	Colesevelam Hydrochloride (Welchol)FDA Link 09/2013 - 10/2007
4	Pioglitazone (Actos)FDA Link 01/2012 - 12/2006
4	C-Reactive ProteinIBA 09/2011 - 10/2008
3	EnzymesIBA 10/2021 - 03/2009
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2018 - 12/2011
3	Pravastatin (Pravachol)FDA LinkGeneric 08/2014 - 03/2003
3	Nonesterified Fatty Acids (NEFA)IBA 01/2014 - 09/2007
3	Cholesterol Ester Transfer ProteinsIBA 12/2013 - 07/2003
3	Glucose (Dextrose)FDA LinkGeneric 09/2013 - 06/2003
3	cerivastatin (Kazak)FDA Link 03/2013 - 09/2002
3	darapladibIBA 05/2011 - 04/2008
3	Oxidoreductases (Dehydrogenase)IBA 01/2009 - 01/2003
3	Fish OilsIBA 05/2008 - 03/2008
2	Corn Oil (Oil, Corn)IBA 05/2021 - 12/2020
2	AntibodiesIBA 01/2021 - 07/2003
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 05/2009
2	Lipoprotein(a)IBA 01/2020 - 01/2019
2	alirocumabIBA 01/2019 - 01/2018
2	omega-Chloroacetophenone (Mace)IBA 12/2016 - 12/2013
2	Complement System Proteins (Complement)IBA 06/2015 - 03/2015
2	Transaminases (Aminotransferases)IBA 06/2014 - 05/2007
2	Docosahexaenoic AcidsIBA 01/2014 - 11/2012
2	LDL Receptors (LDL Receptor)IBA 01/2014 - 03/2011
2	microsomal triglyceride transfer proteinIBA 01/2014 - 12/2013
2	Phytosterols (Plant Sterols)IBA 02/2011 - 03/2003

Therapy/Procedure

63	Therapeutics 01/2022 - 11/2002
7	Secondary Prevention 01/2020 - 07/2003
2	Glycemic Control 09/2013 - 04/2008
2	Drug Therapy (Chemotherapy) 04/2013 - 10/2011